CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Comparator: MK7009 +1 moredrug
Likely dose
MK7009 once daily for 8 days or twice daily for 7 days plus one additional dose on Day 8AI-extracted
Key inclusion· 3
  • ✓Age 18 to 55 years
  • ✓Chronic Hepatitis C infection
  • ✓Willing to abstain from alcohol for 2 weeks prior to therapy and through study follow-up
Key exclusion· 3
  • ✕Advanced liver disease
  • ✕HIV co-infection
  • ✕Hepatitis B co-infection

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00518622
NCT00518622Phase 1Completed
CompareCT.gov

A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients

Merck Sharp & Dohme LLC·interventional·Posted Aug 21, 2007·Updated Aug 25, 2015

In Brief

A Phase 1 clinical trial evaluating Comparator: MK7009 and Comparator: Placebo for Hepatitis C. Completed, enrolled 40 participants.

Detailed Summary

The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 21, 2007
Enrollment StartJul 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.9 years ago

Interventions

Comparator: MK7009drug

Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.

Comparator: Placebodrug

MK7009 Placebo